Doxazosin Alleviates Chronic Orofacial Pain

Area of Science:

• Neuroscience
• Pharmacology
• Pain Research

Background:

• The noradrenergic system, particularly alpha-2 (NAα2) and alpha-1 (NAα1) receptors, plays a dual role in pain processing.
• Acute pain involves NAα2-mediated inhibition, while chronic pain can involve locus coeruleus-driven NAα1-mediated pain promotion.

Purpose of the Study:

• To investigate the effects of a selective NAα1 receptor antagonist, doxazosin, on chronic inflammatory pain and associated behaviors.
• To explore the underlying mechanisms, including glial activation and neurochemical changes, and potential sex differences.

Main Methods:

• Utilized a rat model of chronic inflammatory trigeminal nerve compression (FRICT-ION).
• Administered slow-release doxazosin to rats over a two-week period.
• Assessed facial hypersensitivity, anxiety-like behaviors (elevated zero maze), cognitive function (novel recognition), and glial activation markers (cathepsin B, GFAP).

Main Results:

• Doxazosin reversed facial hypersensitivity in both male and female rats.
• Anxiety was reduced only in male rats, while novel recognition improved only in female rats.
• Doxazosin decreased astrocytic activation in the somatosensory cortex and hippocampus, reducing glial-neuronal interactions and pain behaviors.
• Elevated thymus chemokine CXCL7 levels were reduced by doxazosin exclusively in male rats.

Conclusions:

• NAα1 receptor antagonism with doxazosin can ameliorate chronic inflammatory pain by reducing glial activation and restoring a more inhibitory noradrenergic tone.
• Sex-specific effects on anxiety and cognitive behaviors highlight the complexity of the noradrenergic system and its modulation.
• Findings suggest that targeting NAα1 receptors may shift the locus coeruleus's role from pain promotion to pain inhibition.